In the cell and gene therapy industry's recent performance, what has been most impressive is the series of historical firsts reported in just three months, from December 2023 to the end of February 2024. This includes： 1.the first-ever CRISPR/Cas9 gene editing treatment product, CASGEVY™, which has been approved for market in the United States, United Kingdom, European Union, Saudi Arabia, and Bahrain； 2.the first T-cell therapy for solid tumors, AMTAGVI™, which received FDA approval in the United States. However, the market's investment does not seem to reflect these achievements well. These significant breakthroughs often require longer times to reach the market than traditional drugs, and the accessibility and affordability for patients pose significant challenges. These continue to challenge the ongoing development of the field.
Our 2023 cell and gene therapy sector data is now available! How did the sector shape up? 🔬 Developer and trial presence remains strong with 2500+ developers and nearly 2,000 ongoing trials 🤝 After blockbuster years in 2020 and 2021, yearly investment totals continue to trend at pre-2020 figures Digest the highlights in the images below or dive into the full data on our website: https://lnkd.in/ebVuvmKK